IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025
IRADIMED (NASDAQ: IRMD) has announced its upcoming fourth quarter and full year 2024 financial results conference call, scheduled for February 13, 2025. The company will release its financial results before the market opens, followed by a conference call at 11:00 a.m. Eastern Time.
Management will host the call to discuss results and answer questions. Interested participants can register online to receive dial-in information and a unique pin. The call will be available in real-time via the internet on the company's investor relations website, and a recording will be made available afterward.
IRADIMED (NASDAQ: IRMD) ha annunciato la sua prossima conferenza telefonica sui risultati finanziari del quarto trimestre e dell'intero anno 2024, programmata per il 13 febbraio 2025. L'azienda pubblicherà i risultati finanziari prima dell'apertura del mercato, seguita da una conferenza telefonica alle 11:00 ora orientale.
La direzione ospiterà la chiamata per discutere i risultati e rispondere alle domande. I partecipanti interessati possono registrarsi online per ricevere le informazioni per la chiamata e un PIN unico. La chiamata sarà disponibile in tempo reale tramite internet sul sito web delle relazioni con gli investitori dell'azienda, e una registrazione sarà disponibile in seguito.
IRADIMED (NASDAQ: IRMD) ha anunciado su próxima conferencia telefónica sobre los resultados financieros del cuarto trimestre y del año completo 2024, programada para el 13 de febrero de 2025. La compañía publicará sus resultados financieros antes de la apertura del mercado, seguida de una conferencia telefónica a las 11:00 a.m. hora del Este.
La dirección llevará a cabo la llamada para discutir los resultados y responder preguntas. Los participantes interesados pueden registrarse en línea para recibir información de marcado y un PIN único. La llamada estará disponible en tiempo real a través de internet en el sitio web de relaciones con los inversores de la compañía, y una grabación estará disponible después.
IRADIMED (NASDAQ: IRMD)는 2024년 4분기 및 연간 재무 결과에 대한 전화 회의를 2025년 2월 13일로 예정했다고 발표했습니다. 회사는 시장 개장 전에 재무 결과를 발표하고, 동부 표준시 기준 오전 11시에 전화 회의가 진행됩니다.
경영진이 결과를 논의하고 질문에 답하기 위해 회의를 주최합니다. 관심 있는 참가자는 온라인으로 등록하여 다이얼 인 정보와 고유 PIN을 받을 수 있습니다. 전화 회의는 회사의 투자자 관계 웹사이트를 통해 실시간으로 제공되며, 이후에 녹음본이 제공됩니다.
IRADIMED (NASDAQ: IRMD) a annoncé sa prochaine conférence téléphonique sur les résultats financiers du quatrième trimestre et de l'année 2024, prévue pour le 13 février 2025. L'entreprise publiera ses résultats financiers avant l'ouverture du marché, suivis d'une conférence téléphonique à 11h00 heure de l'Est.
La direction animera l'appel pour discuter des résultats et répondre aux questions. Les participants intéressés peuvent s'inscrire en ligne pour recevoir les informations de connexion et un code PIN unique. L'appel sera disponible en temps réel via Internet sur le site Web des relations avec les investisseurs de l'entreprise, et un enregistrement sera disponible par la suite.
IRADIMED (NASDAQ: IRMD) hat seine bevorstehende Telefonkonferenz zu den finanziellen Ergebnissen des vierten Quartals und des gesamten Jahres 2024 angekündigt, die für den 13. Februar 2025 angesetzt ist. Das Unternehmen wird seine finanziellen Ergebnisse vor der Markteröffnung veröffentlichen, gefolgt von einer Telefonkonferenz um 11:00 Uhr Eastern Time.
Das Management wird die Konferenz moderieren, um die Ergebnisse zu besprechen und Fragen zu beantworten. Interessierte Teilnehmer können sich online registrieren, um Dial-In-Informationen und eine einzigartige PIN zu erhalten. Die Konferenz wird in Echtzeit über das Internet auf der Investor-Relations-Website des Unternehmens verfügbar sein, und eine Aufnahme wird anschließend bereitgestellt.
- None.
- None.
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BI94f1f3be82df46ccb09997e06cb41e49
Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit www.iradimed.com for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
When will IRMD release its Q4 2024 earnings?
What time is IRMD's Q4 2024 earnings conference call?
How can investors join IRMD's Q4 2024 earnings call?
Will IRMD's Q4 2024 earnings call be recorded?
